Ani Pharmaceuticals Stock Performance
| ANIP Stock | USD 64.26 0.09 0.14% |
On a scale of 0 to 100, ANI Pharmaceuticals holds a performance score of 9. The firm shows a Beta (market volatility) of 1.06, which signifies a somewhat significant risk relative to the market. ANI Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, ANI Pharmaceuticals is expected to follow. Please check ANI Pharmaceuticals' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether ANI Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ANI Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak forward indicators, ANI Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.14) | Five Day Return 2.31 | Year To Date Return 15.91 | Ten Year Return (3.44) | All Time Return (69.94) |
Last Split Factor 1:6 | Last Split Date 2013-07-18 |
1 | Disposition of 400 shares by Meredith Cook of ANI Pharmaceuticals at 59.54 subject to Rule 16b-3 | 02/13/2025 |
2 | ANI Pharmaceuticals Inc Announces Upcoming Release of Q4 and Full Year 2024 Financial Results | 02/19/2025 |
3 | ANI Pharmaceuticals Inc Reports Q4 2024 Earnings EPS of 1.63 and Revenue of 190. ... | 02/28/2025 |
4 | ANI Pharmaceuticals Downgraded to Sell Rating by StockNews.com | 03/04/2025 |
5 | Heres Why Ensign Group Can be a Smart Addition to Your Portfolio | 03/10/2025 |
6 | 1 Growth Stock to Target This Week and 2 to Avoid | 03/12/2025 |
7 | Relative Price Strength A Smart Strategy Amid Market Turmoil | 03/13/2025 |
8 | ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUV | 03/14/2025 |
9 | AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study | 03/17/2025 |
10 | ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and YUTIQ | 03/18/2025 |
11 | SRPT Nosedives 27 percent on Patient Death Following DMD Therapy Infusion | 03/19/2025 |
12 | ANI Pharmaceuticals Inc Completes Buyout of Royalty Obligation to SWK Funding LLC | 03/21/2025 |
| Begin Period Cash Flow | 221.1 M |
ANI |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,421 in ANI Pharmaceuticals on December 23, 2024 and sell it today you would earn a total of 1,005 from holding ANI Pharmaceuticals or generate 18.54% return on investment over 90 days. ANI Pharmaceuticals is currently generating 0.3096% in daily expected returns and assumes 2.5318% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than ANI, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ANI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ANI Pharmaceuticals, and traders can use it to determine the average amount a ANI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1223
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANIP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.53 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.31 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average ANI Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ANI Pharmaceuticals by adding it to a well-diversified portfolio.
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | -0.0418 | ||||
| Return On Asset | 0.0084 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.9 B | ||||
| Shares Outstanding | 21.76 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.46 X | ||||
| Price To Sales | 2.28 X | ||||
| Revenue | 614.38 M | ||||
| Gross Profit | 364.17 M | ||||
| EBITDA | 63.12 M | ||||
| Net Income | (18.52 M) | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 314.98 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 20.54 X | ||||
| Cash Flow From Operations | 64.02 M | ||||
| Earnings Per Share | (1.04) X | ||||
| Market Capitalization | 1.4 B | ||||
| Total Asset | 1.28 B | ||||
| Retained Earnings | (100.28 M) | ||||
| Working Capital | 334 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
About ANI Pharmaceuticals Performance
Assessing ANI Pharmaceuticals' fundamental ratios provides investors with valuable insights into ANI Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ANI Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 201.24 | 184.50 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Assets | (0.01) | (0.02) | |
| Return On Equity | (0.04) | (0.05) |
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 614.38 M. Net Loss for the year was (18.52 M) with profit before overhead, payroll, taxes, and interest of 364.17 M. | |
| ANI Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: ANI Pharmaceuticals Inc Completes Buyout of Royalty Obligation to SWK Funding LLC |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.